donepezil
AssetAlso DKF-310, Aricept, Donepezil HCl, Donepezil hydrochloride
Reversible acetylcholinesterase inhibitor that elevates synaptic acetylcholine levels.
- Stage
- Approved
- Modality
- Small molecule
- Target
- ACHE
- 16
- Indications
- 153
- Trials
- 5
- Developers
Indications
16Dementia
Approved, accessdata.fda.gov, 7 Oct 2026
Alzheimer's disease
Phase 3, Completed, NCT00477659, clinicaltrials.gov, 7 Oct 2026
Attention impairment
Phase 3, Completed, NCT00688376, clinicaltrials.gov, 7 Oct 2026
13 more
In the full profile
- Targets and what it contains1
- Owner and partners5
- Trials153
- Evidence for its targets2
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 32 sources